The decisions that determine Phase 2 timing are made, or missed, in the first two quarters after the IND opens.
White Paper
IND Ready Is Not Phase 2 Ready
Related Resources
All Resources
case-study
Regulatory Operations Department Developed and Flourishing
Read More
case-study
Successful US/EU Marketing Applications for Big Pharma
Read More
post
Overview of FDA Expedited Development and Approval Programs for Serious Conditions
Read More
post
The Push for Patient-Focused Drug Development
Read More
Let's move from science to success.
Let’s Talk